SUMIT K. SUBUDHI to CTLA-4 Antigen
This is a "connection" page, showing publications SUMIT K. SUBUDHI has written about CTLA-4 Antigen.
Connection Strength
1.490
-
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na?ve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer. 2021 10; 9(10).
Score: 0.606
-
New approaches to immunotherapy for metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2019 May; 17(5):283-286.
Score: 0.128
-
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 08 31; 128(9):3813-3818.
Score: 0.122
-
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019 02 15; 25(4):1233-1238.
Score: 0.122
-
Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun. 2016 08 08; 7:12335.
Score: 0.106
-
Immune Checkpoint Therapies in Prostate Cancer. Cancer J. 2016 Mar-Apr; 22(2):117-20.
Score: 0.103
-
Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology. 2012 Jun; 217(6):590-2.
Score: 0.076
-
Improving the therapeutic benefits of ipilimumab. Oncology (Williston Park). 2010 Dec; 24(14):1288, 1294.
Score: 0.072
-
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. J Immunother Cancer. 2021 05; 9(5).
Score: 0.037
-
Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell. 2019 Nov 14; 179(5):1177-1190.e13.
Score: 0.033
-
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res. 2019 06 01; 25(11):3469-3470.
Score: 0.032
-
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 12; 24(12):1804-1808.
Score: 0.031
-
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014 Mar 05; 6(226):226ra32.
Score: 0.022